Ovarian Cancer Early Detection Screening Program
The program will offer twice yearly CA-125 blood tests and annual transvaginal ultrasounds
to monitor women at high risk for ovarian cancer. In addition to the main purpose of
providing ovarian cancer screening, the researchers would also like to build a repository of
blood specimens for use in ovarian and breast cancer research and to offer genetics
counseling sessions to help educate women about risk-reducing options.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Measuring for elevated levels of tumor marker CA-125 in the blood over time.
Average expected time of 1 year
No
Pamela Paley, MD
Principal Investigator
Swedish Medical Center
United States: Institutional Review Board
IR 4707
NCT01292733
August 2009
August 2015
Name | Location |
---|---|
Marsha Rivkin Center for Ovarian Cancer Research | Seattle, Washington 98122 |